Lytix Biopharma is a company committed to the health and lives of cancer patients and to serve their unmet needs. Our vision is to add improved treatment options to the existing ones to the benefit of patients.
Far too many cancer patients experience resistance to today’s treatment options or recurrence of disease. Inspired by the immunotherapy breakthroughs we have seen continue over the past decade, we are dedicated to strengthening the spark of hope ignited by immune checkpoint inhibitors, and to bringing their curative result to even more patients.
Today’s immune checkpoint inhibitors have been used in the treatment of cancer patients for more than 10 years, and the majority of melanoma patients that have responded to this treatment have not seen any symptoms of cancer during these years.
The proportion of patients that respond to today’s treatment still is too limited, but we expect more patients to experience improved health and longevity from cancer immunotherapy in the future. An immense amount of time and resources is put into the refinement and improvement of this kind of therapies, both from academic researchers and the life science industry.
We have with all our resources joined this effort, and Lytix Biopharma is today a Phase II clinical stage immuno-oncology company with more than 20 years of preclinical and clinical research. Our approach is based on injecting oncolytic drugs directly into the tumors. The small molecules kill cancer cells in a unique way that generates a broad immune response that fights cancer.
Our treatment option has an acceptable safety profile, and it works very well in combination with other types of cancer treatment, with no added toxicity. We are very much looking forward to seeing the results that will emerge from several clinical Phase II trials now ongoing with our lead drug candidate, LTX-315.